Xeris is growing its pipeline through both internal clinical development and external partnerships in order to advance the commercial potential of its products globally.


Xeris is interested in establishing a portfolio of strategic collaborations with key partners who wish to co-develop products using Xeris’ platform technologies (XeriSol™ and XeriJect®). Currently, Xeris is working on a number of formulation feasibility programs in the areas of small molecules, peptides, biologics, and monoclonal antibodies. We welcome the opportunity to discuss areas of potential common interest upon which to build value for both parties. To discuss partnering opportunities, please contact us.